724 related articles for article (PubMed ID: 33325008)
41. Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review.
Liarakos AL; Koliaki C
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509514
[TBL] [Abstract][Full Text] [Related]
42. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
Gastaldelli A; Cusi K; Fernández Landó L; Bray R; Brouwers B; Rodríguez Á
Lancet Diabetes Endocrinol; 2022 Jun; 10(6):393-406. PubMed ID: 35468325
[TBL] [Abstract][Full Text] [Related]
43. Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program.
Frías JP; Galindo RJ; Wang H; Malik RE; Chivukula KK; Maldonado JM
J Clin Endocrinol Metab; 2024 Jan; 109(2):557-568. PubMed ID: 37602701
[TBL] [Abstract][Full Text] [Related]
44. Tirzepatide: First Approval.
Syed YY
Drugs; 2022 Jul; 82(11):1213-1220. PubMed ID: 35830001
[TBL] [Abstract][Full Text] [Related]
45. Separate and combined effects of long-term GIP and GLP-1 receptor activation in patients with type 2 diabetes: a structured summary of a study protocol for a double-blind, randomised, placebo-controlled clinical trial.
Helsted MM; Gasbjerg LS; Vilsbøll T; Nielsen CK; Forman JL; Christensen MB; Knop FK
BMJ Open; 2023 Feb; 13(2):e065736. PubMed ID: 36849212
[TBL] [Abstract][Full Text] [Related]
46. Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data.
Goldenberg RM; Teoh H; Verma S
Curr Opin Cardiol; 2023 Nov; 38(6):539-545. PubMed ID: 37792556
[TBL] [Abstract][Full Text] [Related]
47. Structural determinants of dual incretin receptor agonism by tirzepatide.
Sun B; Willard FS; Feng D; Alsina-Fernandez J; Chen Q; Vieth M; Ho JD; Showalter AD; Stutsman C; Ding L; Suter TM; Dunbar JD; Carpenter JW; Mohammed FA; Aihara E; Brown RA; Bueno AB; Emmerson PJ; Moyers JS; Kobilka TS; Coghlan MP; Kobilka BK; Sloop KW
Proc Natl Acad Sci U S A; 2022 Mar; 119(13):e2116506119. PubMed ID: 35333651
[TBL] [Abstract][Full Text] [Related]
48. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.
Thomas MK; Nikooienejad A; Bray R; Cui X; Wilson J; Duffin K; Milicevic Z; Haupt A; Robins DA
J Clin Endocrinol Metab; 2021 Jan; 106(2):388-396. PubMed ID: 33236115
[TBL] [Abstract][Full Text] [Related]
49. Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3.
Viljoen A; Pantalone KM; Galindo RJ; Cui X; Huh R; Hemmingway A; Fernández Landó L; Patel H
Diabetes Ther; 2023 May; 14(5):925-936. PubMed ID: 37000390
[TBL] [Abstract][Full Text] [Related]
50. Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus.
Alqifari SF; Alkomi O; Esmail A; Alkhawami K; Yousri S; Muqresh MA; Alharbi N; Khojah AA; Aljabri A; Allahham A; Prabahar K; Alshareef H; Aldhaeefi M; Alrasheed T; Alrabiah A; AlBishi LA
World J Diabetes; 2024 Mar; 15(3):331-347. PubMed ID: 38591071
[TBL] [Abstract][Full Text] [Related]
51. Tirzepatide: A Systematic Update.
Forzano I; Varzideh F; Avvisato R; Jankauskas SS; Mone P; Santulli G
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498958
[TBL] [Abstract][Full Text] [Related]
52. Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP.
Wang L
Drug Des Devel Ther; 2022; 16():1547-1559. PubMed ID: 35651477
[TBL] [Abstract][Full Text] [Related]
53. The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects.
Jensen TL; Brønden A; Karstoft K; Sonne DP; Christensen MB
Patient Prefer Adherence; 2024; 18():373-382. PubMed ID: 38352159
[TBL] [Abstract][Full Text] [Related]
54. Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist: A Single-Center Case Series Study.
Kubota M; Yamamoto K; Yoshiyama S
Cureus; 2023 Oct; 15(10):e46490. PubMed ID: 37800161
[TBL] [Abstract][Full Text] [Related]
55. Perspectives on weight control in diabetes - Tirzepatide.
Várkonyi TT; Pósa A; Pávó N; Pavo I
Diabetes Res Clin Pract; 2023 Aug; 202():110770. PubMed ID: 37279858
[TBL] [Abstract][Full Text] [Related]
56. The new dual gastric inhibitory peptide/glucagon-like peptide 1 agonist tirzepatide in type 2 diabetes: Is the future bright?
Papachristou S; Popovic DS; Papanas N
Diabetes Metab Res Rev; 2021 Nov; 37(8):e3503. PubMed ID: 34626443
[TBL] [Abstract][Full Text] [Related]
57. The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis.
Wilson JM; Lin Y; Luo MJ; Considine G; Cox AL; Bowsman LM; Robins DA; Haupt A; Duffin KL; Ruotolo G
Diabetes Obes Metab; 2022 Jan; 24(1):148-153. PubMed ID: 34542221
[TBL] [Abstract][Full Text] [Related]
58. Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges.
Huang X; Liu J; Peng G; Lu M; Zhou Z; Jiang N; Yan Z
J Endocrinol; 2024 Jun; ():. PubMed ID: 38916409
[TBL] [Abstract][Full Text] [Related]
59. Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide.
Boye KS; Sapin H; Dong W; Williamson S; Lee CJ; Thieu VT
Diabetes Ther; 2023 Nov; 14(11):1867-1887. PubMed ID: 37668888
[TBL] [Abstract][Full Text] [Related]
60. Incretin hormones: Their role in health and disease.
Nauck MA; Meier JJ
Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
